Man­u­fac­tur­ing roundup: Bio­con ac­quires New Jer­sey man­u­fac­tur­ing site for $7M+; Ghana­ian man­u­fac­tur­er to fill-fin­ish cholera vac­cine

Bio­con Gener­ics, a sub­sidiary of In­dia-based man­u­fac­tur­er Bio­con, has ac­quired an oral med­i­cine pro­duc­tion fa­cil­i­ty in Cran­bury, NJ, from gener­ic man­u­fac­tur­er Ey­wa Phar­ma for $7.7 mil­lion.

The deal closed on Sept. 1, and staff at the site will trans­fer to Bio­con Gener­ics, ac­cord­ing to a press re­lease. The site can pro­duce two bil­lion tablets per year, but no de­tails on what ex­act­ly will be made were dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.